---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-24-000108"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:07:58.083592+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Senti Bio receives Nasdaq deficiency notice for audit committee composition

## Summary
- On Oct 22, 2024, Nasdaq notified Senti Bio that its audit committee has only two members, violating Listing Rule 5605(c)(2)(A).
- Vacancy resulted from Susan Berland’s resignation from the board effective June 11, 2024.
- Cure period: until Dec 9, 2024 (since next annual meeting already held) or June 11, 2025, whichever earlier.
- No immediate impact on listing or trading of SNTI common stock on Nasdaq Capital Market.
- Company evaluating committee membership and intends to regain compliance before cure deadline.

## SEC filing metadata
- accession: 0001854270-24-000108
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000108/0001854270-24-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000108/snti-20241022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-24-000108
- JSON: https://secwatch.observer/filing/0001854270-24-000108.json
- Plain text: https://secwatch.observer/filing/0001854270-24-000108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.